New mouthwash helps with pain linked to head and neck cancerFebruary 02, 2006Doctors in Italy are studying whether a new type of mouthwash will help alleviate pain for patients suffering from head and neck cancer who were treated with radiation therapy, according to a study published in the February 1, 2006, issue of the International Journal of Radiation OncologyBiologyPhysics, the official journal of ASTRO, the American Society for Therapeutic Radiology and Oncology. Fifty patients, suffering from various forms of head and neck cancer and who received radiation therapy as part of their treatment, were observed during the course of their radiation treatment. Mucositis, or inflammation of the mucous membrane in the mouth, is the most common side effect for these patients yet no additional therapy has been identified that successfully reduces the pain. All of the patients experienced some level of pain related to their cancer treatment and this study sought to discover if a mouthwash made from the local anesthetic tetracaine was able to alleviate the discomfort associated with head and neck cancer and if there would be any negative side effects of the mouthwash. The doctors chose to concoct a tetracaine-based mouthwash instead of a lidocaine-based version because it was found to be four times more effective, worked faster and produced a prolonged relief. The tetracaine was administered by a mouthwash approximately 30 minutes before and after meals, or roughly six times a day. Relief of oral pain was reported in 48 of the 50 patients. Sixteen patients reported that the mouthwash had an unpleasant taste or altered the taste of their food. "Though our study is relatively small, we found that the tetracaine-based mouthwash reduced oral pain, without any relevant side effects, in a sizeable number of our studied patients. With more testing, this could become a more common way to treat this side effect," said Daniela Alterio, M.D., lead author of the study and a radiation oncologist at the European Institute of Oncology in Milan, Italy. "Oral pain is one of the most common side effects of radiation therapy for head and neck cancers, so this is great news for patients undergoing that treatment." American Society for Therapeutic Radiology and Oncology |
|||||||||||||||||||||
| Related Neck Cancer Current Events and Neck Cancer News Articles PMH finding may help some tonsil cancer patients avoid chemotherapy Clinical researchers at Princess Margaret Hospital (PMH) have confirmed that patients with oropharyngeal squamous cell cancer ("tonsil cancer") harbour a common type of human papilloma virus (HPV16), but also that such cancers are very sensitive to radiation. New laryngoscope could make difficult intubations easier A new tool developed by a Medical College of Georgia resident and faculty member may make it easier to place assisted breathing devices under difficult circumstances. Rare head and neck cancer linked to HPV, study finds An increase in cases of a rare type of head and neck cancer appears to be linked to HPV, or human papillomavirus, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center. Curcumin may inhibit nicotine-induced activation of head and neck cancers Curcumin, the compound that gives curry powder its yellow/orange color, may inhibit the adverse effects of nicotine in patients with head and neck cancer who continue to smoke. Study finds 231 new genes associated with head and neck cancer A Henry Ford Hospital study has identified 231 new genes associated with head and neck cancer, one of the most deadly cancers responsible for 2.1 percent of all cancer deaths in the United States. U of T researchers create microchip that can detect type and severity of cancer U of T researchers have used nanomaterials to develop a microchip sensitive enough to quickly determine the type and severity of a patient's cancer so that the disease can be detected earlier for more effective treatment. Identification of highly radiosensitive patients may lead to side effect-free radiotherapy An international group of scientists has taken the first step on the road to targeting radiotherapy dosage to individual patients by means of their genetic characteristics. Adding cetuximab to chemotherapy reduces advanced lung cancer death risk by 13 percent Patients with advanced non-small cell lung cancer who are given cetuximab (Erbitux) in addition to chemotherapy are 13% less likely to die than those who receive chemotherapy alone, regardless of which chemotherapy drug cocktail is used, new research finds. They also experience slower disease progression and an increased chance of tumour shrinkage. Prevent periodontitis to reduce the risk of head and neck cancer Chronic periodontitis, a form of gum disease, is an independent risk factor for head and neck squamous cell carcinoma. This suggests the need for increased efforts to prevent and treat periodontitis as a possible means to reduce the risk of this form of cancer. Prodrug could help curb skin toxicity related to EGFR-inhibiting cancer drugs There may be a way around the harsh skin toxicity associated with a widely used cancer drug, according to a study published online this week in Cancer Biology and Therapy by researchers from City of Hope and the Kimmel Cancer at Jefferson. More Neck Cancer Current Events and Neck Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||